FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / News / Read News


Solar Capital, Deerfield Management Form First Lien Life Science Loan Program

February 23, 2017, 07:11 AM
Filed Under: Life Sciences

Solar Capital Ltd. and Solar Senior Capital Ltd. announced that they have formed Solar Life Science Program LLC with Deerfield Management. Founded in 1994, Deerfield Management is a private investment firm with over $8 billion in assets under management. The firm specializes in healthcare investing, from seed stage to mature companies across all segments of healthcare.

Including anticipated leverage, LSJV's total investable capital is expected to be approximately $700 million. LSJV is expected to invest the majority of its assets in first lien loans to publicly-traded companies in the U.S. life science industry. Aside from the larger enterprise value of the targeted companies, the business model is consistent with the loans currently being originated by Solar Capital Partners' life science lending team.

Solar Capital, Solar Senior, affiliates of the joint venture between Solar Capital Partners and PIMCO, and Deerfield Management have committed equity capital of up to $350 million to LSJV, subject to certain conditions. The individual organizations' specific commitments are $50 million, $75 million, $75 million and $150 million, respectively. Once a sufficient number of investments have been made, LSJV is expected to be levered up to approximately 1.0x debt-to-equity, based on discussions with third party debt providers. LSJV is expected to generate a mid-to-high-teens return on equity, consistent with the returns Solar Capital and Solar Senior have achieved on their realized life science investments to date.

"We are thrilled to add another initiative to our life science platform through this partnership with Deerfield Management," said Michael Gross, Chairman and CEO of Solar Capital Ltd and Solar Senior Capital Ltd. "LSJV enables our life science team to include public, later stage, larger enterprise value companies in our target market. In our opinion, these larger companies present an attractive investment opportunity due to their more advanced product pipeline, as well as their access to public equity capital. We view Deerfield's expertise in the healthcare sector as a valuable addition to the initiative."

Week's News

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.